Atro Medical

Executive Summary

Atro Medical is a Dutch clinical-stage medical device company developing the Artimis® meniscus prosthesis, an artificial meniscus implant designed to treat chronic knee pain following meniscectomy. Founded in 2016 as a spin-off from Radboudumc and DSM, the company targets the significant unmet need in patients who are too young for total knee replacement but suffer from post-meniscectomy syndrome. The Artimis implant aims to preserve the knee joint and delay the need for arthroplasty, thereby improving quality of life. Atro Medical is currently conducting clinical studies in multiple Dutch hospitals to evaluate the safety and efficacy of its device. The company's innovative approach addresses a large patient population, with potential to become a standard-of-care for meniscus-deficient knees. As a private, Phase 1 company, Atro Medical has yet to disclose funding details but has progressed through early clinical development. The success of its ongoing trials will be critical for regulatory approvals and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Interim clinical data from ongoing study70% success
• 2027CE Mark submission or approval50% success
• Q2 2026Series A funding round completion60% success